Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doris Auth

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
JAMA Internal Medicine|May 5, 2020
Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy ProgramDoris Auth, Judy Staffa, Cynthia LaCivita
The Journal of Continuing Education in the Health Professions|January 8, 2019
A Collaboration Between Government and the Continuing Education Community Tackles the Opioid Crisis: Lessons Learned and Future OpportunitiesNorman Kahn, Kathy Chappell, Kate Regnier, et al.
JAMA Network Open|March 30, 2019
Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl PrescribingWilliam Fleischman, Doris Auth, Nilay D Shah, et al.
Drug Safety|February 10, 2021
Risk Management for the 21st Century: Current Status and Future NeedsRania Mouchantaf, Doris Auth, Yola Moride, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric CancerSandra J Casak, Yiming Zhang, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract CancerSandra J Casak, Vaibhav Kumar, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other RearrangementsShruti U Gandhy, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerMichael J Fusco, Sandra J Casak, Sirisha L Mushti, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
JAMA Internal Medicine|May 5, 2020
Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy ProgramDoris Auth, Judy Staffa, Cynthia LaCivita
The Journal of Continuing Education in the Health Professions|January 8, 2019
A Collaboration Between Government and the Continuing Education Community Tackles the Opioid Crisis: Lessons Learned and Future OpportunitiesNorman Kahn, Kathy Chappell, Kate Regnier, et al.
JAMA Network Open|March 30, 2019
Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl PrescribingWilliam Fleischman, Doris Auth, Nilay D Shah, et al.
Drug Safety|February 10, 2021
Risk Management for the 21st Century: Current Status and Future NeedsRania Mouchantaf, Doris Auth, Yola Moride, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric CancerSandra J Casak, Yiming Zhang, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract CancerSandra J Casak, Vaibhav Kumar, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal CancerSandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other RearrangementsShruti U Gandhy, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerMichael J Fusco, Sandra J Casak, Sirisha L Mushti, et al.
Pageof 1